Abstract: Systems and methods for managing resistance to insecticidal traits and chemicals are provided. In one aspect, systems and methods are provided that: 1) delay the development of resistance to transgenic insecticidal crops and/or chemical insecticides (preemptive strategies), and 2) rescue one or more pests' susceptibility to transgenic insecticidal crops and/or chemical insecticides once pest resistance has developed (responsive strategies).
Type:
Grant
Filed:
December 22, 2016
Date of Patent:
January 2, 2024
Assignee:
Provivi, Inc.
Inventors:
John B. Schoper, Pedro Coelho, Christopher Wheeler
Abstract: The present invention relates to stable liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable oral suspensions of baclofen at concentrations of equal to or more than 2 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions of baclofen are suitable for oral administration and are stable at wider pH ranges over a variety of storage conditions, including long-term storage for extended periods of time. Methods of treating various disorders using the inventive pharmaceutical compositions are also provided. The invention further relates to various methods for preparing stable suspension of baclofen.
Abstract: Control or repellency of biting arthropods, particularly biting insects, is accomplished by bringing the biting arthropods into contact with combinations of compounds identical or related to those found on human/animal skin or in plants acting synergistically with one another, or in combination with conventional repellents like N,N-diethyl-3-methylbenzamide (DEET®), para-menthane-3,8-diol (PMD), sec-butyl-2-(2-hydroxyethyl) piperidine carboxylate (“Picaridin”), or other nitrogen containing repellents selected from amines, amides and nitrogen containing heterocyclic compounds, or any synergistic combination of DEET®, PMD, Picaridin, or other nitrogen containing repellents selected from amines, amides and nitrogen containing heterocyclic compounds.
Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. In the formula (I), each symbol is as defined in the specification.
Abstract: Aqueous formulations of indacaterol are disclosed. The formulations may find use in the treatment of respiratory disorders, inflammatory disorders, or obstructive airway diseases. Methods of using the formulations and kits comprising the formulations are also encompassed by the disclosure.
Type:
Grant
Filed:
September 29, 2021
Date of Patent:
December 19, 2023
Assignee:
AERORX THERAPEUTICS LLC
Inventors:
John Chan, Keith Try Ung, Mei-Chang Kuo, John Nigel Pritchard
Abstract: Nordihydroguaiaretic acid (NDGA) derivatives, including terameprocol (TMP) have utility as anti-viral agents for use on patients infected with or at risk of infection with a coronavirus, including SARS-CoV-2. In vitro studies show coronavirus-infected cells treated with 0.2 ?M-20 ?M TMP show reduced viral RNA activity in vitro. Treatment-related cytotoxicity is not shown at 0.2 ?M TMP with a low percentage of cytotoxicity shown at 5 ?M TMP. In application, the NDGA derivatives may be administered to a patient intravenously at a molar concentration of 0.1-50 ?M or orally at a molar concentration of 0.1-100 ?M.
Abstract: Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing.
Type:
Grant
Filed:
June 30, 2021
Date of Patent:
December 12, 2023
Assignee:
MannKind Corporation
Inventors:
Edwin Amoro, Karel Vanackere, Michael A. White
Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-?B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
Type:
Grant
Filed:
October 28, 2020
Date of Patent:
December 5, 2023
Assignee:
ReveraGen BioPharma, Inc.
Inventors:
John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
Abstract: Provided herein are compositions for treating biofilm-derived infections include a cis-monounsaturated fatty acid solubilized in a solvent with a concentration in the range of about 100 ppm (parts per million) to about 1000 ppm, where the composition is configured to produce a bactericidal effect measured as a log reduction of colony forming units (CFU) of a bacteria of at least 1.0 when the composition is applied to a biofilm formed from the bacteria. Also provided are methods for treating the site of a biofilm-derived infection comprising applying a composition as disclosed herein to the site.
Type:
Grant
Filed:
March 5, 2021
Date of Patent:
November 28, 2023
Assignee:
DePuy Synthes Products, Inc.
Inventors:
Malavosklish Bikram-Liles, Charles Florek, David A. Armbruster, Shireen Shaikh, Kyra Woloszczuk
Abstract: Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.
Abstract: Provided is a pharmaceutical composition comprising suplatast tosilate or pharmaceutically acceptable derivatives thereof that provides for a constant exposure of the compound.
Type:
Grant
Filed:
August 28, 2018
Date of Patent:
November 21, 2023
Assignees:
Conrig Pharma ApS, Solural Pharma ApS
Inventors:
John Bondo Hansen, Mikael Søndergård Thomsen, Bent Højgaard
Abstract: The present disclosure relates to novel sesquiterpenoid compounds as SHP2 and/or POLE3 inhibitors for potential treatment for cancers, and to methods of making and using the sesquiterpenoid compounds. The present invention therefore provides a method of using the disclosed compounds as chemosensitizations agent to a DNA damaging drugs for cancers.
Type:
Grant
Filed:
May 3, 2021
Date of Patent:
November 14, 2023
Assignees:
Purdue Research Foundation, University of Florida Research Foundation, Inc.
Inventors:
Mingji Dai, Dexter Cameron Davis, Alexander Adibekian, Dominic Gregor Hoch, Zhong-Yin Zhang
Abstract: A therapeutic composition for topical delivery of a metalloporphyrin to the hoof region of an equine leg suffering from laminitis is provided. Also provided is a method of reducing the degree of an injury to the hoof of an equine that is the result of laminitis. The method results in a reduced period for recovery and reduces the possibility of euthanasia of the animal.
Abstract: The present invention provides a method for treating a liver disorder or lipid disorder in a subject in need thereof with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile, a stereoisomer, a salt thereof, or a morphic form thereof.
Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.
Abstract: The present disclosure provides compounds useful as anesthetics, such as topical anesthetics, of general formula (VI): wherein: R1 is H, Cl, F, —CF3, —OCF3, —OMe, or methyl; R8 is selected from the group consisting of: —NH2, —N(H)Alk, —N(Alk)2, R7 is H or alkyl; m is 3 to 6; p is 1 to 4; q is 1 to 4; p+g is 3 to 6; and each Alk is independently an aliphatic carbon group consisting of 1 to 6 carbon atoms, and methods of making and using same.
Type:
Grant
Filed:
November 30, 2022
Date of Patent:
November 7, 2023
Assignee:
PTC Innovations, LLC
Inventors:
Pendleton Wickersham, Stephen Bendel, Todd Mathis, Christian Warren
Abstract: Preparations and formulations capable of crossing and incorporating into a membrane of a cell or an organelle or an exosome are described. Methods of treatments utilizing the preparations and formulations are also described.
Abstract: The present invention provides materials and methods for making a subject non-responsive to an antigen. Methods of the invention may comprise contacting the subject with the antigen and a compound that induces anergy. In some embodiments, the antigen may be an autoimmune antigen, examples of which include, but are not limited to acetylcholine receptor for myasthenia gravis, glutamic acid decarboxylase for type I diabetes mellitus and rheumatoid factor in rheumatoid arthritis. In some embodiments, the present invention provides a method of transplanting an organ, tissue, or cells into a subject (e.g. a mammal such as a human).